Looking for Merkel cell cancer cells in blood before and after surgery
Treatments studied
Part of Cancer, Infections clinical trials.
This study looks for Merkel cell carcinoma cells in the blood before and after surgery (and/or radiation). It may help researchers understand how these cells change with treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have Merkel cell carcinoma that is stage I, II, or III (has not spread to distant parts of the body).
- Your doctor plans to remove all visible cancer with surgery, or you had surgery in the last 6 weeks that removed all visible cancer.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This study looks at how people with Merkel cell carcinoma take part in clinical trials. It helps researchers understand what helps or makes it hard for patients to join and stay in studies.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.